secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dermata Therapeutics, Inc. (DRMA)
CIK:        0001853816
Form:       8-K
Filed at:   2022-06-24T23:59:59+00:00
Accession:  0001654954-22-008770
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Dermata promotes Nardo to Chief Development Officer; CEO takes 20% pay cut
--------------------------------------------------------------------------

- Christopher Nardo promoted to SVP, Chief Development Officer effective July 1, 2022.
- Nardo granted option for 30,000 shares; vests 25% after one year, then monthly over 36 months.
- Nardo's base salary increased to $320,000 from $280,000 per year.
- CEO Gerald Proehl reduces salary from $350,000 to $280,000 per year effective same date.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1853816/000165495422008770/0001654954-22-008770-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1853816/000165495422008770/drma_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-22-008770

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer